Search results for "Expanded disability status scale"

showing 10 items of 46 documents

The Impact of Coconut Oil and Epigallocatechin Gallate on the Levels of IL-6, Anxiety and Disability in Multiple Sclerosis Patients

2020

Background: Due to the inflammatory nature of multiple sclerosis (MS), interleukin 6 (IL-6) is high in blood levels, and it also increases the levels of anxiety related to functional disability. Epigallocatechin gallate (EGCG) decreases IL-6, which could be enhanced by the anti-inflammatory effect of high ketone bodies after administering coconut oil (both of which are an anxiolytic). Therefore, the aim of this study was to assess the impact of coconut oil and EGCG on the levels of IL-6, anxiety and functional disability in patients with MS. Methods: A pilot study was conducted for four months with 51 MS patients who were randomly divided into an intervention group and a control group. The …

Male0301 basic medicineTime FactorsMediterranean dietEmotionsPilot ProjectsEpigallocatechin gallateDiet Mediterraneanmultiple sclerosisGastroenterologyCatechinBody Mass IndexDisability Evaluationchemistry.chemical_compound0302 clinical medicineProspective Studiescoconut oilNutrition and DieteticsCoconut oilfood and beveragesMiddle AgedMultiple Sclerosis Chronic ProgressiveanxietyTreatment OutcomeAnxietyFemalemedicine.symptomlcsh:Nutrition. Foods and food supplyepigallocatechin gallatemedicine.medical_specialtyfood.ingredientmedicine.drug_classlcsh:TX341-641PlaceboAnxiolyticArticle03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingfoodInternal medicinemedicineHumansExpanded Disability Status Scalebusiness.industryinterleukin-6Recovery of Function030104 developmental biologydisabilitychemistrySpainDietary SupplementsbusinessBody mass indexBiomarkers030217 neurology & neurosurgeryFood ScienceNutrients
researchProduct

Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines…

2016

Palmitoylethanolamide (PEA) is an endogenous lipid mediator known to reduce pain and inflammation. However, only limited clinical studies have evaluated the effects of PEA in neuroinflammatory and neurodegenerative diseases. Multiple sclerosis (MS) is a chronic autoimmune and inflammatory disease of the central nervous system. Although subcutaneous administration of interferon (IFN)-β1a is approved as first-line therapy for the treatment of relapsing–remitting MS (RR-MS), its commonly reported adverse events (AEs) such as pain, myalgia, and erythema at the injection site, deeply affect the quality of life (QoL) of patients with MS. In this randomized, double-blind, placebo-controlled study,…

Male0301 basic medicinemyalgiaErythemaAnti-Inflammatory AgentsPalmitic AcidAdministration OralPharmacologyGastroenterologychemistry.chemical_compound0302 clinical medicineNeuroinflammationFAAHEthanolaminePharmacology (medical)SkinInterleukin-17food and beveragesAnti-Inflammatory AgentTolerabilityEthanolaminesDisease ProgressionCytokinesOriginal ArticleFemalemedicine.symptomInterferon beta-1aHumanAdultmedicine.medical_specialtyPainPalmitic AcidsProinflammatory cytokineInterferon-gamma03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingDouble-Blind MethodInternal medicinemedicineHumansAdverse effectCytokinePharmacologyPalmitoylethanolamideExpanded Disability Status ScaleTumor Necrosis Factor-alphabusiness.industryMultiple sclerosisN-acylethanolamineOleoylethanolamideAnandamideNAAAmedicine.diseaseAmides030104 developmental biologychemistryNeurology (clinical)business030217 neurology & neurosurgeryNeurotherapeutics
researchProduct

Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis

2014

Objective White matter atrophy occurs independently of lesions in multiple sclerosis. In contrast to lesion detection, the quantitative assessment of white matter atrophy in individual patients has been regarded as a major challenge. We therefore tested the hypothesis that white matter atrophy (WMA) is present at the very beginning of multiple sclerosis (MS) and in virtually each individual patient. To find a new sensitive and robust marker for WMA we investigated the relationship between cortical surface area, white matter volume (WMV), and whole-brain-surface-averaged rectified cortical extrinsic curvature. Based on geometrical considerations we hypothesized that cortical curvature increa…

MalePathologyROI region of interestFOV field of viewlcsh:RC346-429ImagingGRAPPA generalized autocalibrating partially parallel acquisitionCortex (anatomy)Image Processing Computer-AssistedFA fractional anisotropyWMV white matter volumeTE echo timeCerebral Cortexmedicine.diagnostic_testEVAL Münster Neuroimaging Evaluation SystemMiddle AgedMagnetic Resonance ImagingWhite MatterTR repetition timemedicine.anatomical_structureNeurologyGMV gray matter volumeCerebral cortexCortexlcsh:R858-859.7FemaleAlzheimer's diseasePsychologyCIS clinically isolated syndromeMRITSE turbo spin-echoAdultmedicine.medical_specialtyAdolescentCognitive NeuroscienceCortical curvatureICV intracranial volumelcsh:Computer applications to medicine. Medical informaticsCurvatureArticleEDSS Expanded Disability Status ScaleMultiple sclerosisWhite matterYoung AdultAtrophyAlzheimer DiseasemedicineHumansRadiology Nuclear Medicine and imagingWM white matterlcsh:Neurology. Diseases of the nervous systemAgedMultiple sclerosis3D three-dimensionaleWMV estimated white matter volumeMagnetic resonance imagingmedicine.diseaseΔWMV WMV − eWMVCI confidence intervalCase-Control StudiesGM gray matterAnisotropyDTI diffusion tensor imagingNeurology (clinical)AtrophySD standard deviationDemyelinating DiseasesNeuroImage: Clinical
researchProduct

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results…

2009

Background Cognitive impairment is a common symptom of multiple sclerosis (MS), but the association between cognitive impairment and magnetic resonance imaging (MRI) disease measures in patients with relapsing–remitting (RR) MS is unclear. Objectives To study the prevalence of cognitive impairment and its relation with MRI disease measures in mildly disabled patients with RRMS. Methods Patients aged 18–50 years with RRMS (McDonald criteria) and an Expanded Disability Status Scale (EDSS) score ≤4.0, who were enrolled in the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study, underwent baseline standardized MRI complete neurological examination and neuropsychological testing. Results…

MalePediatricsIntelligenceRelapsing-RemittingNeuropsychological TestsSeverity of Illness IndexDisability EvaluationCognitionRisk FactorsOdds RatioPrevalenceNeuropsychological assessmentProspective StudiesNeurologic Examinationmedicine.diagnostic_testCognitive impairmet. Cognitive function. Multiple Sclerosis. Neuropsychological assessment.Cognitive disorderNeuropsychologyAge FactorsMiddle AgedMagnetic Resonance ImagingCognitive testTreatment OutcomeNeurologyItalyFemaleSettore MED/26 - NeurologiaPsychologyAdultmedicine.medical_specialtyMultiple SclerosisAdolescentNeurological examinationRisk AssessmentYoung AdultMultiple Sclerosis Relapsing-RemittingPredictive Value of TestsMagnetic Resonance Imaging; Young Adult; Age Factors; Odds Ratio; Immunologic Factors; Humans; Multiple Sclerosis Relapsing-Remitting; Cognition; Italy; Risk Assessment; Adult; Treatment Outcome; Adolescent; Neuropsychological Tests; Male; Severity of Illness Index; Neurologic Examination; Interferon-beta; Predictive Value of Tests; Cognition Disorders; Cross-Sectional Studies; Intelligence; Prospective Studies; Risk Factors; Disability Evaluation; Middle Aged; Female; PrevalencemedicineHumansImmunologic FactorsExpanded Disability Status ScaleMultiple sclerosisMcDonald criteriaInterferon-betamedicine.diseaseCross-Sectional StudiesPhysical therapyNeurology (clinical)Cognition Disorders
researchProduct

Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis

2021

Importance Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging. Objective To evaluate changes in the prognosis of POMS over time in association with changes in therapeutic and managing standards. Design, Setting, and Participants Retrospective, multicenter, observational study. Data were extracted and collected in May 2019 from the Italian MS Registry, a digital database including more than 59 000 patients. Inclusion criteria were…

MaleRegistriePediatricsAdolescent; Adult; Age of Onset; Aged; Child; Child Preschool; Female; Humans; Italy; Male; Middle Aged; Multiple Sclerosis; Registries; Retrospective Studies; Risk Factors; Young Adult; Disabled Persons; Disease ProgressionRisk of Disability0302 clinical medicineRisk FactorsRetrospective StudieMultiple Sclerosi030212 general & internal medicineRegistriesAge of OnsetChildOriginal InvestigationHazard ratioConfoundingMiddle Agedpediatric-onset MS (POMS)Italytherapeutic and managing standardsChild PreschoolDisease ProgressionSettore MED/26 - NeurologiaFemaleDisabled PersonHumanAdultmedicine.medical_specialtyMultiple SclerosisAdolescentMEDLINEProfile of mood states03 medical and health sciencesYoung AdultmedicineHumansIn patientDisabled PersonsPreschoolpediatric-onset MS (POMS) therapeutic and managing standardsRetrospective StudiesAgedExpanded Disability Status Scalebusiness.industryPediatric-Onset Multiple SclerosisMultiple sclerosisRisk Factormedicine.diseaseObservational studyNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting …

2010

The objective of this study was to assess the effects of subcutaneous (sc) interferon beta-1a (IFNβ-1a) on cognition in mildly disabled patients with relapsing—remitting multiple sclerosis (RRMS). Patients aged 18—50 years with RRMS (McDonald criteria; Expanded Disability Status Scale score ≤4.0) were assigned IFNβ therapy at the physician’s discretion and underwent standardized magnetic resonance imaging, neurological examination and neuropsychological testing at the baseline and regular intervals for up to three years. This analysis included 459 patients who received sc IFNβ-1a (44 mcg: n = 236; 22 mcg: n = 223; three-year follow up was available for 318 patients). The hazard ratio for c…

Maleinterferon beta-1aKaplan-Meier EstimateRelapsing-RemittingNeuropsychological TestsCohort StudiesDisability EvaluationMedicineMale; Adolescent; Young Adult; Middle Aged; Kaplan-Meier Estimate; Cognition Disorders; Survival Analysis; Female; Disability Evaluation; Dose-Response Relationship Drug; Humans; Multiple Sclerosis Relapsing-Remitting; Prospective Studies; Cohort Studies; Disease Progression; Interferon-beta; Injections Subcutaneous; Neuropsychological Tests; Adult; Immunologic Factors; Endpoint DeterminationProspective StudiesProspective cohort studyinterferon beta multiple sclerosis cognitive impairmentSubcutaneousCognitive disorderHazard ratioMiddle AgedSettore MED/26 - NEUROLOGIANeurologyDisease ProgressionSettore MED/26 - NeurologiaFemaleDrugmedicine.drugAdultmedicine.medical_specialtyMultiple SclerosisAdolescentEndpoint DeterminationInjections SubcutaneousLower riskInjectionsDose-Response RelationshipYoung AdultMultiple Sclerosis Relapsing-RemittingInternal medicineHumansImmunologic Factorscognitive functioncognitive impairmentExpanded Disability Status ScaleDose-Response Relationship Drugbusiness.industryInterferon beta-1aMcDonald criteriaOdds ratioInterferon-betamedicine.diseaseSurvival AnalysisSurgerydisabilityNeurology (clinical)businessCognition Disorderscognitive function; cognitive impairment; disability; disease progression; interferon beta-1a; multiple sclerosis
researchProduct

Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study

2021

Background and purpose: Tumefactive multiple sclerosis (TuMS) (i.e., MS onset presenting with tumefactive demyelinating lesions [TDLs]) is a diagnostic and therapeutic challenge. We performed a multicentre retrospective study to describe the clinical characteristics and the prognostic factors of TuMS. Methods: One hundred two TuMS patients were included in this retrospective study. Demographic, clinical, magnetic resonance imaging (MRI), laboratory data and treatment choices were collected. Results: TuMS was found to affect women more than men (female:male: 2.4), with a young adulthood onset (median age: 29.5 years, range: 11–68 years, interquartile range [IQR]: 38 years). At onset, 52% of …

Maletumefactive demyelinating lesions (TDLs)0302 clinical medicineRetrospective StudieInterquartile rangedifferential diagnosis030212 general & internal medicineProspective StudiesYoung adultProspective cohort studyChildtreatmentTumefactive multiple sclerosiTumefactive demyelinating lesionsDemyelinating DiseaseMiddle AgedMagnetic Resonance ImagingDifferential diagnosis Multiple sclerosis Tumefactive demyelinating lesions Tumefactive multiple sclerosisNeurologydifferential diagnosis; Multiple sclerosis; Tumefactive demyelinating lesions; Tumefactive multiple sclerosisFemaleHumanAdultmedicine.medical_specialtyMultiple SclerosisAdolescentdifferential diagnosiSettore MED/26Multiple sclerosis03 medical and health sciencesYoung AdultTumefactive multiple sclerosisOligoclonal BandInternal medicinemedicineHumansMultiple sclerosiTumefactive multiple sclerosisTumefactive multiple sclerosis (TuMS)AgedRetrospective StudiesTumefactive demyelinating lesionExpanded Disability Status Scalebusiness.industryOligoclonal BandsRetrospective cohort studyOdds ratiomedicine.diseaseConfidence intervalProspective Studiedifferential diagnosis; Multiple sclerosis; Tumefactive demyelinating lesions; Tumefactive multiple sclerosis; Adolescent; Adult; Aged; Child; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Oligoclonal Bands; Prospective Studies; Retrospective Studies; Young Adult; Demyelinating Diseases; Multiple SclerosisprognosisNeurology (clinical)business030217 neurology & neurosurgeryDemyelinating Diseases
researchProduct

Predictors of Participation and Autonomy in People With Multiple Sclerosis.

2019

Abstract Importance: Because multiple sclerosis (MS) affects many life areas, it is important to know how participation and autonomy are associated with the perceived impact of MS on everyday life. Objective: To investigate how perceived quality of life, disease impact, gender, and disease severity predict participation and autonomy in people with MS. Design: Cross-sectional study in which structural equation modeling was used to evaluate relationships between measured variables. Settings: Outpatient clinics in three areas and one inpatient rehabilitation center in Finland. Participants: Convenience sample of 194 people with MS. Outcomes and Measures: Participants completed the Impact on Pa…

Occupational therapyGerontology030506 rehabilitationmedicine.medical_specialtyExpanded Disability Status ScaleMultiple Sclerosismedia_common.quotation_subjectPsychological interventionStructural equation modeling03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Cross-Sectional StudiesOccupational TherapyScale (social sciences)medicineQuality of LifeOutpatient clinicHumans0305 other medical sciencePsychology030217 neurology & neurosurgeryAutonomyResearch Articlesmedia_commonThe American journal of occupational therapy : official publication of the American Occupational Therapy Association
researchProduct

Covarying patterns of white matter lesions and cortical atrophy predict progression in early MS

2020

ObjectiveWe applied longitudinal 3T MRI and advanced computational models in 2 independent cohorts of patients with early MS to investigate how white matter (WM) lesion distribution and cortical atrophy topographically interrelate and affect functional disability.MethodsClinical disability was measured using the Expanded Disability Status Scale Score at baseline and at 1-year follow-up in a cohort of 119 patients with early relapsing-remitting MS and in a replication cohort of 81 patients. Covarying patterns of cortical atrophy and baseline lesion distribution were extracted by parallel independent component analysis. Predictive power of covarying patterns for disability progression was tes…

OncologyAdultMalemedicine.medical_specialtySupport Vector Machine41Article312LesionWhite matterText miningMultiple Sclerosis Relapsing-RemittingInternal medicineCerebellumMedicineHumansLongitudinal StudiesCerebral CortexExpanded Disability Status Scalemedicine.diagnostic_testbusiness.industryMultiple sclerosisMagnetic resonance imagingMiddle Agedmedicine.diseasePrognosisMagnetic Resonance ImagingWhite MatterHyperintensitymedicine.anatomical_structureNeurologyCohortDisease ProgressionFemaleNeurology (clinical)medicine.symptomAtrophybusinessNeurology® Neuroimmunology & Neuroinflammation
researchProduct

Apolipoprotein E genotype does not influence the progression of multiple sclerosis

2003

OBJECTIVE: To investigate the association between apolipoprotein E (APOE) polymorphisms and the progression of MS. METHODS: We investigated 428 subjects affected by clinically defined MS, with a disease duration of at least three years. We collected data concerning the age at onset of MS, clinical type, disease duration and disability according to the expanded disability status scale (EDSS). We also calculated the progression index (PI) to evaluate disease progression. APOE genotyping and the -491 A/T polymorphism of the APOE promoter were determined. RESULTS: No association was observed between the APOE epsilon4 allele and clinical characteristics of our study population. We also investiga…

OncologyApolipoprotein EAdultMalemedicine.medical_specialtyMultiple SclerosisGenotypeAdolescentOdds Ratio; Polymorphism Genetic; Chi-Square Distribution; Humans; Disease Progression; Apolipoproteins E; Genotype; Multiple Sclerosis; Adult; Confidence Intervals; Adolescent; Statistics Nonparametric; Female; MalePopulationAPOE polymorphismBiologyStatistics NonparametricApolipoproteins EGeneticPolymorphism (computer science)Internal medicineGenotypeMultiple SclerosimedicineOdds RatioConfidence IntervalsHumansNonparametricPolymorphismeducationGenotypingAPOE promotereducation.field_of_studyExpanded Disability Status ScalePolymorphism GeneticChi-Square DistributionMS progressionStatisticsOdds ratioNeurologyImmunologyDisease ProgressionPopulation studylipids (amino acids peptides and proteins)FemaleSettore MED/26 - NeurologiaNeurology (clinical)Confidence IntervalHuman
researchProduct